Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients

Michael J Miyashiro1, Samuel C Lo2, Jeanette A Stewart3, William C Stewart31Ludwig Ophthalmology Centre, Hilo, HI, USA; 2Private Practice, Honolulu, HI, USA; 3PRN Pharmaceutical Research Network, LLC, Dallas, TX, USAObjective: To examine the efficacy, safety, and tolerability of travoprost 0.004% be...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Michael J Miyashiro, Samuel C Lo, Jeanette A Stewart, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/6744a45f669f4b3a8435921137859dc0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6744a45f669f4b3a8435921137859dc0
record_format	dspace
spelling	oai:doaj.org-article:6744a45f669f4b3a8435921137859dc02021-12-02T07:36:14ZEfficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients1177-54671177-5483https://doaj.org/article/6744a45f669f4b3a8435921137859dc02010-11-01T00:00:00Zhttp://www.dovepress.com/efficacy-safety-and-tolerability-of-travoprost-0004-bak-free-versus-pr-a5728https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Michael J Miyashiro1, Samuel C Lo2, Jeanette A Stewart3, William C Stewart31Ludwig Ophthalmology Centre, Hilo, HI, USA; 2Private Practice, Honolulu, HI, USA; 3PRN Pharmaceutical Research Network, LLC, Dallas, TX, USAObjective: To examine the efficacy, safety, and tolerability of travoprost 0.004% benzalkonium chloride (BAK)-free compared with previous use of latanoprost 0.005% in Japanese patients living in the US who had primary open-angle glaucoma or ocular hypertension.Methods: This was an open-label, multicenter, bilateral, intraindividual, and active-controlled study in which 20 Japanese American patients with primary open-angle glaucoma or ocular hypertension who had been on latanoprost 0.005% monotherapy were changed to monotherapy with travoprost 0.004% BAK-free daily for 12 weeks. Patients were administered the same series of tests to evaluate the efficacy, safety, and tolerability of latanoprost at the baseline visit and of travoprost BAK-free at the week 12 visit.Results: No significant difference in mean intraocular pressure (IOP) was observed between latanoprost monotherapy at baseline and travoprost BAK-free monotherapy after 12 weeks (P = 0.76), nor were significant differences noted in mean ocular hyperemia, visual acuity, corneal fluorescein staining, or overall scores from the Ocular Surface Disease Index. Patients had a significantly shorter mean tear breakup time while on latanoprost compared with travoprost BAK-free (P = 0.0094). Significantly more patients preferred travoprost BAK-free monotherapy over latanoprost monotherapy (14 versus 6; P = 0.011).Conclusion: The results of this study suggest that Japanese American patients transitioned from latanoprost 0.005% monotherapy to travoprost 0.004% BAK-free can expect similar IOP control and some improvement in anterior segment signs. This transition study showed a strong patient preference for travoprost BAK-free over latanoprost, at a ratio of more than 2:1.Keywords: glaucoma, intraocular pressure, latanoprost, prostaglandin analog, travoprost Michael J MiyashiroSamuel C LoJeanette A Stewartet alDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2010, Iss default, Pp 1355-1359 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Michael J Miyashiro Samuel C Lo Jeanette A Stewart et al Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
description	Michael J Miyashiro1, Samuel C Lo2, Jeanette A Stewart3, William C Stewart31Ludwig Ophthalmology Centre, Hilo, HI, USA; 2Private Practice, Honolulu, HI, USA; 3PRN Pharmaceutical Research Network, LLC, Dallas, TX, USAObjective: To examine the efficacy, safety, and tolerability of travoprost 0.004% benzalkonium chloride (BAK)-free compared with previous use of latanoprost 0.005% in Japanese patients living in the US who had primary open-angle glaucoma or ocular hypertension.Methods: This was an open-label, multicenter, bilateral, intraindividual, and active-controlled study in which 20 Japanese American patients with primary open-angle glaucoma or ocular hypertension who had been on latanoprost 0.005% monotherapy were changed to monotherapy with travoprost 0.004% BAK-free daily for 12 weeks. Patients were administered the same series of tests to evaluate the efficacy, safety, and tolerability of latanoprost at the baseline visit and of travoprost BAK-free at the week 12 visit.Results: No significant difference in mean intraocular pressure (IOP) was observed between latanoprost monotherapy at baseline and travoprost BAK-free monotherapy after 12 weeks (P = 0.76), nor were significant differences noted in mean ocular hyperemia, visual acuity, corneal fluorescein staining, or overall scores from the Ocular Surface Disease Index. Patients had a significantly shorter mean tear breakup time while on latanoprost compared with travoprost BAK-free (P = 0.0094). Significantly more patients preferred travoprost BAK-free monotherapy over latanoprost monotherapy (14 versus 6; P = 0.011).Conclusion: The results of this study suggest that Japanese American patients transitioned from latanoprost 0.005% monotherapy to travoprost 0.004% BAK-free can expect similar IOP control and some improvement in anterior segment signs. This transition study showed a strong patient preference for travoprost BAK-free over latanoprost, at a ratio of more than 2:1.Keywords: glaucoma, intraocular pressure, latanoprost, prostaglandin analog, travoprost
format	article
author	Michael J Miyashiro Samuel C Lo Jeanette A Stewart et al
author_facet	Michael J Miyashiro Samuel C Lo Jeanette A Stewart et al
author_sort	Michael J Miyashiro
title	Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
title_short	Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
title_full	Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
title_fullStr	Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
title_full_unstemmed	Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
title_sort	efficacy, safety, and tolerability of travoprost 0.004% bak-free versus prior treatment with latanoprost 0.005% in japanese patients
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/6744a45f669f4b3a8435921137859dc0
work_keys_str_mv	AT michaeljmiyashiro efficacysafetyandtolerabilityoftravoprost0004bakfreeversuspriortreatmentwithlatanoprost0005injapanesepatients AT samuelclo efficacysafetyandtolerabilityoftravoprost0004bakfreeversuspriortreatmentwithlatanoprost0005injapanesepatients AT jeanetteastewart efficacysafetyandtolerabilityoftravoprost0004bakfreeversuspriortreatmentwithlatanoprost0005injapanesepatients AT etal efficacysafetyandtolerabilityoftravoprost0004bakfreeversuspriortreatmentwithlatanoprost0005injapanesepatients
_version_	1718399341423493120

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients

Ejemplares similares